Item 7.01. Regulation FD Disclosure.
On June 4, 2021, SQZ Biotechnologies Company (the “Company”) issued a press
release titled “SQZ Biotechnologies Initial First-In-Human Data Demonstrates
Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in
Certain Patients with Advanced or Metastatic HPV16+ Tumors.” A copy of the press
release is attached hereto as Exhibit 99.1.
The Company is also furnishing a corporate presentation, attached as Exhibit
99.2 to this Current Report on Form 8-K, which the Company intends to use from
time to time in meetings with investors and others beginning on June 4, 2021.
The corporate presentation will also be available in the investor relations
section of the Company’s website at http://sqzbiotech.com.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto
shall not be deemed “filed” for purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, nor shall they be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release issued by SQZ Biotechnologies Company on June 4, 2021. 99.2 SQZ Biotechnologies Company Corporate Presentation.
© Edgar Online, source Glimpses